US-based SpringWorks Therapeutics, which specialises on developing medicines and treatments for cancers and severe rare diseases, has raised $125m in a series B funding round led by Perceptive Advisors.

The financing round was joined by GlaxoSmithKline, Boxer Capital, HBM Healthcare Investments, BVF Partners, Surveyor Capital, Samsara BioCapital, ArrowMark Partners and Laurion Capital Management.

It also included participation from Pfizer, LifeArc, OrbiMed and Bain Capital, among other investors.

SpringWorks Therapeutics will use the funds to advance two of its late-stage rare oncology programmes into potential regulatory approval and commercialisation stages.

One of the programmes is looking into nirogacestat, a gamma secretase inhibitor being developed to treat desmoid tumours. The second programme involves research into the PD-0325901 MEK inhibitor for neurofibromatosis type 1-associated plexiform neurofibromas.

“SpringWorks Theraputics is well positioned to continue developing its rare disease and targeted oncology platforms.”

The proceeds will also support the continued expansion of the Company’s emerging targeted oncology programs, as well as future in-licensing opportunities and clinical collaborations in rare diseases and cancer.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company expects to launch three clinical trials in the first half of this year.

These include studies of the two rare oncology programmes, and a trial in alliance with China-based BeiGene to assess its first targeted oncology candidate.

SpringWorks Therapeutics CEO Saqib Islam said: “This financing from a committed, knowledgeable and distinguished investor syndicate, which includes new and existing investors as well as key industry partners, underscores the progress we’ve made to advance our late-stage clinical programs towards pivotal studies, execute on our initial business development strategy, and build upon our leading drug development operations.

“We are well positioned to continue to execute on our strategy to build a leading rare disease and targeted oncology company that brings promising science to underserved patient communities.”

SpringWorks Therapeutics was launched in 2017 with licensed clinical therapies from Pfizer.